PT3166937T - Compostos antiproliferativos e métodos de uso dos mesmos - Google Patents
Compostos antiproliferativos e métodos de uso dos mesmosInfo
- Publication number
- PT3166937T PT3166937T PT157394859T PT15739485T PT3166937T PT 3166937 T PT3166937 T PT 3166937T PT 157394859 T PT157394859 T PT 157394859T PT 15739485 T PT15739485 T PT 15739485T PT 3166937 T PT3166937 T PT 3166937T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- antiproliferative compounds
- antiproliferative
- compounds
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462023775P | 2014-07-11 | 2014-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3166937T true PT3166937T (pt) | 2019-12-12 |
Family
ID=53682892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT157394859T PT3166937T (pt) | 2014-07-11 | 2015-07-10 | Compostos antiproliferativos e métodos de uso dos mesmos |
Country Status (30)
Country | Link |
---|---|
US (6) | US9499514B2 (pt) |
EP (2) | EP3594211B1 (pt) |
JP (3) | JP6779870B2 (pt) |
KR (1) | KR102477960B1 (pt) |
CN (2) | CN111170991B (pt) |
AR (1) | AR101189A1 (pt) |
AU (1) | AU2015287688B2 (pt) |
BR (1) | BR112017000550B1 (pt) |
CA (1) | CA2954784C (pt) |
CL (1) | CL2017000075A1 (pt) |
CO (1) | CO2017000223A2 (pt) |
CY (1) | CY1122340T1 (pt) |
DK (1) | DK3166937T3 (pt) |
EA (1) | EA033633B1 (pt) |
EC (1) | ECSP17002135A (pt) |
ES (2) | ES2968308T3 (pt) |
HR (1) | HRP20191821T1 (pt) |
HU (1) | HUE046000T2 (pt) |
IL (2) | IL276946B (pt) |
LT (1) | LT3166937T (pt) |
MX (2) | MX2017000408A (pt) |
PL (1) | PL3166937T3 (pt) |
PT (1) | PT3166937T (pt) |
RS (1) | RS59619B1 (pt) |
SA (1) | SA517380693B1 (pt) |
SG (2) | SG10202010780WA (pt) |
SI (1) | SI3166937T1 (pt) |
TW (1) | TWI660952B (pt) |
WO (1) | WO2016007848A1 (pt) |
ZA (1) | ZA201700217B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体による併用療法 |
MX2017007208A (es) * | 2014-12-04 | 2018-01-30 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de leucemia mieloide aguda. |
CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
EP3310386B1 (en) | 2015-06-22 | 2021-07-21 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
LT3827845T (lt) | 2015-11-03 | 2022-06-10 | Janssen Biotech, Inc. | Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US10648983B2 (en) * | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
MX367669B (es) * | 2016-01-08 | 2019-08-30 | Celgene Corp | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos. |
TWI733734B (zh) * | 2016-01-08 | 2021-07-21 | 美商西建公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式,及其醫藥組合物及用途 |
EA037508B1 (ru) * | 2016-01-08 | 2021-04-06 | Селджин Корпорейшн | Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
US10245258B2 (en) * | 2016-06-06 | 2019-04-02 | Celgene Corporation | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
CN106928253A (zh) * | 2017-03-09 | 2017-07-07 | 武汉工程大学 | 一种唑啉草酯的制备方法 |
CA3068591A1 (en) * | 2017-06-30 | 2019-01-03 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
CN107827721B (zh) * | 2017-11-17 | 2021-03-16 | 上海恩氟佳科技有限公司 | 一种合成4-氟环己酮的方法 |
US20210069356A1 (en) * | 2018-01-02 | 2021-03-11 | Celgene Corporation | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
US11530219B2 (en) | 2018-06-29 | 2022-12-20 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
BR112021012578A2 (pt) * | 2018-12-31 | 2021-09-08 | Celgene Corporation | Composições e métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
CN114269729A (zh) | 2019-05-31 | 2022-04-01 | 细胞基因公司 | 经取代1-氧代-异吲哚啉-5-羧酰胺化合物,其组合物,及以此治疗的方法 |
CN114901281A (zh) * | 2019-11-05 | 2022-08-12 | 细胞基因公司 | 与2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的组合疗法 |
GB201916600D0 (en) * | 2019-11-14 | 2020-01-01 | Syngenta Crop Protection Ag | 81991-gb-reg-org-nat-1 |
AU2020387392A1 (en) * | 2019-11-19 | 2022-07-14 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of Helios protein |
US11312699B2 (en) | 2019-12-06 | 2022-04-26 | Celgene Corporation | Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
IL299293A (en) | 2020-06-25 | 2023-02-01 | Celgene Corp | Cancer treatment methods with combined treatments |
JP2023541522A (ja) * | 2020-08-03 | 2023-10-03 | キャプター セラピューティクス エス.エー. | 低分子量タンパク質分解物質及びその適用 |
MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
CN118019534A (zh) * | 2021-05-06 | 2024-05-10 | 细胞基因公司 | 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法 |
EP4091449A1 (en) * | 2021-05-19 | 2022-11-23 | Syngenta Crop Protection AG | Weed control method |
EP4398942A1 (en) * | 2021-09-08 | 2024-07-17 | Orum Therapeutics Inc. | Linkers for use in antibody drug conjugates |
WO2024027694A1 (zh) * | 2022-08-01 | 2024-02-08 | 苏州开拓药业股份有限公司 | 一种蛋白降解剂 |
WO2024075080A1 (en) * | 2022-10-06 | 2024-04-11 | Orum Therapeutics, Inc. | Neodegrader conjugates |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
RU2230550C2 (ru) | 1998-01-16 | 2004-06-20 | Такеда Кемикал Индастриз, Лтд. | Композиции длительного высвобождения, способ их получения и применение |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
MX2009001989A (es) * | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
SI2358697T1 (sl) | 2008-10-29 | 2016-02-29 | Celgene Corporation | Spojine izoindolina za uporabo pri zdravljenju raka |
US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
EA037508B1 (ru) | 2016-01-08 | 2021-04-06 | Селджин Корпорейшн | Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
TWI733734B (zh) | 2016-01-08 | 2021-07-21 | 美商西建公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式,及其醫藥組合物及用途 |
MX367669B (es) | 2016-01-08 | 2019-08-30 | Celgene Corp | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos. |
US10245258B2 (en) | 2016-06-06 | 2019-04-02 | Celgene Corporation | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2015
- 2015-07-09 US US14/795,837 patent/US9499514B2/en active Active
- 2015-07-10 IL IL276946A patent/IL276946B/en unknown
- 2015-07-10 SG SG10202010780WA patent/SG10202010780WA/en unknown
- 2015-07-10 AR ARP150102218A patent/AR101189A1/es unknown
- 2015-07-10 HU HUE15739485A patent/HUE046000T2/hu unknown
- 2015-07-10 EP EP19193334.0A patent/EP3594211B1/en active Active
- 2015-07-10 JP JP2017522462A patent/JP6779870B2/ja active Active
- 2015-07-10 DK DK15739485.9T patent/DK3166937T3/da active
- 2015-07-10 KR KR1020177003826A patent/KR102477960B1/ko active IP Right Grant
- 2015-07-10 CA CA2954784A patent/CA2954784C/en active Active
- 2015-07-10 MX MX2017000408A patent/MX2017000408A/es active IP Right Grant
- 2015-07-10 AU AU2015287688A patent/AU2015287688B2/en active Active
- 2015-07-10 EP EP15739485.9A patent/EP3166937B1/en active Active
- 2015-07-10 ES ES19193334T patent/ES2968308T3/es active Active
- 2015-07-10 LT LT15739485T patent/LT3166937T/lt unknown
- 2015-07-10 PT PT157394859T patent/PT3166937T/pt unknown
- 2015-07-10 EA EA201790174A patent/EA033633B1/ru not_active IP Right Cessation
- 2015-07-10 WO PCT/US2015/039926 patent/WO2016007848A1/en active Application Filing
- 2015-07-10 CN CN202010096963.1A patent/CN111170991B/zh active Active
- 2015-07-10 CN CN201580048551.8A patent/CN106660991B/zh active Active
- 2015-07-10 BR BR112017000550-6A patent/BR112017000550B1/pt active IP Right Grant
- 2015-07-10 SI SI201530944T patent/SI3166937T1/sl unknown
- 2015-07-10 PL PL15739485T patent/PL3166937T3/pl unknown
- 2015-07-10 SG SG11201700126RA patent/SG11201700126RA/en unknown
- 2015-07-10 ES ES15739485T patent/ES2760003T3/es active Active
- 2015-07-10 RS RS20191550A patent/RS59619B1/sr unknown
- 2015-07-13 TW TW104122680A patent/TWI660952B/zh active
-
2016
- 2016-09-23 US US15/275,045 patent/US9808451B2/en active Active
-
2017
- 2017-01-09 SA SA517380693A patent/SA517380693B1/ar unknown
- 2017-01-09 IL IL250008A patent/IL250008B/en active IP Right Grant
- 2017-01-10 ZA ZA2017/00217A patent/ZA201700217B/en unknown
- 2017-01-10 MX MX2020007485A patent/MX2020007485A/es unknown
- 2017-01-11 CL CL2017000075A patent/CL2017000075A1/es unknown
- 2017-01-11 CO CONC2017/0000223A patent/CO2017000223A2/es unknown
- 2017-01-12 EC ECIEPI20172135A patent/ECSP17002135A/es unknown
- 2017-10-02 US US15/723,065 patent/US9968596B2/en active Active
-
2018
- 2018-04-09 US US15/948,904 patent/US20180221361A1/en not_active Abandoned
-
2019
- 2019-06-10 US US16/436,819 patent/US11241423B2/en active Active
- 2019-10-07 HR HRP20191821TT patent/HRP20191821T1/hr unknown
- 2019-12-03 CY CY20191101269T patent/CY1122340T1/el unknown
-
2020
- 2020-10-14 JP JP2020173475A patent/JP2021011495A/ja active Pending
-
2021
- 2021-12-23 US US17/560,972 patent/US20220387413A1/en active Pending
-
2022
- 2022-10-26 JP JP2022171356A patent/JP2023011732A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276946A (en) | Antiproliferative compounds and methods of use | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
LT3215147T (lt) | Neurologinį poveikį mažinantys norketamino junginiai ir būdai | |
ZA201702545B (en) | Neuroactive compounds and methods of use thereof | |
IL251988A0 (en) | Compounds acting on glycans and methods of using them | |
IL253234A0 (en) | Methods for transdifferentiation and methods to use them | |
RS60718B1 (sr) | Jedinjenja i načini upotrebe | |
GB201514760D0 (en) | Compounds and method of use | |
HK1243342A1 (zh) | 化合物和方法 | |
HK1243077A1 (zh) | 呱啶基吡唑並嘧啶酮及其用途 | |
ZA201606450B (en) | Compounds and their methods of use | |
GB201403697D0 (en) | Compounds and methods of use | |
PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
GB201416797D0 (en) | Contianer and method of use thereof | |
GB201413411D0 (en) | Novel compounds and their use |